Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > I-Flow Announces Closing of Acquisition of AcryMed Incorporated

Abstract:
I-FLOW CORPORATION (NASDAQ:IFLO) announced today that it has completed the acquisition of AcryMed Incorporated, a developer of innovative infection control and wound healing products. I-Flow previously announced a binding letter of intent contemplating the acquisition of AcryMed for $25 million in cash.

I-Flow Announces Closing of Acquisition of AcryMed Incorporated

LAKE FOREST, CA | Posted on February 19th, 2008

AcryMed developed the proprietary nanoparticle treatment process for the silver coating on I-Flow's ON-Q® SilverSoakerTM Catheters with SilvaGard® and has been treating the catheters since I-Flow developed the product line in 2005. AcryMed will also manufacture for I-Flow a new line of silver transparent wound-site dressings, which I-Flow expects to bring to market in the first half of this year. In addition to providing silver coating for these I-Flow products, AcryMed is active in researching and developing new wound care technologies and has licensed a portion of these technologies for a range of infection control and wound care products.

AcryMed's patent portfolio consists of a total of 66 worldwide issued and pending patents, including 16 U.S. patents. In addition, its scientific staff includes four Ph.D.s and 10 other scientists who have made AcryMed a leader in silver antimicrobial technologies.

####

About I-FLOW CORPORATION
I-Flow Corporation (www.IFLO.com) currently designs, develops and markets technically advanced, low cost drug delivery systems and services that are redefining the standard of care by providing life enhancing, cost effective solutions for pain relief.

"Safe Harbor" Statement

Statements by the Company in this press release and in other reports and statements released by the Company are and will be forward-looking in nature and express the Company's current opinions about trends and factors that may impact future operating results. Statements that use words such as "may," "will," "should," "believes," "predicts," "estimates," "projects," "anticipates" or "expects" or use similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to material risks, assumptions and uncertainties, which could cause actual results to differ materially from those currently expected, and readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to publish revised forward-looking statements to reflect the occurrence of unanticipated or subsequent events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this press release that seek to advise interested parties of the risks and other factors that affect the Company's business. Interested parties should also review the Company's reports on Forms 10-K, 10-Q and 8-K and other reports that are periodically filed with or furnished to the Securities and Exchange Commission. The risks affecting the Company's business include, among others: physician acceptance of infusion-based therapeutic regimens; implementation of the Company's direct sales strategy; successful integration of the Company's recent acquisition of AcryMed Incorporated and further development and commercialization of AcryMed's technologies; dependence on the Company's suppliers and distributors; the Company's continuing compliance with applicable laws and regulations, such as the Medicare Supplier Standards and the Food, Drug and Cosmetic Act, and Medicare's and the FDA's concurrence with management's subjective judgment on compliance issues; the reimbursement system currently in place and future changes to that system; product availability, acceptance and safety; competition in the industry; technological changes; intellectual property challenges and claims; economic and political conditions in foreign countries; currency exchange rates; inadequacy of booked reserves; and reliance on the success of the home health care industry. All forward-looking statements, whether made in this press release or elsewhere, should be considered in context with the various disclosures made by the Company about its business.

For more information, please click here

Contacts:
I-Flow Corporation
James R. Talevich, Chief Financial Officer
949-206-2700
www.iflo.com
or
Investor Contact:
Berkman Associates
Neil Berkman, 310-826-5051

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Picosun’s ALD nanolaminates improve lifetime and reliability of electronic circuit boards October 24th, 2017

JPK reports the research of the Schwille Group at the Max Planck Institute of Biochemistry near Munich using the NanoWizard® ULTRA Speed AFM October 24th, 2017

Researchers bring optical communication onto silicon chips: Ultrathin films of a semiconductor that emits and detects light can be stacked on top of silicon wafers October 23rd, 2017

Nanotube fiber antennas as capable as copper: Rice University researchers show their flexible fibers work well but weigh much less October 23rd, 2017

Nanomedicine

Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma October 23rd, 2017

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) October 23rd, 2017

Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting(R) 2017 October 23rd, 2017

Spinning strands hint at folding dynamics: Rice University lab uses magnetic beads to model microscopic proteins, polymers October 17th, 2017

Announcements

Picosun’s ALD nanolaminates improve lifetime and reliability of electronic circuit boards October 24th, 2017

JPK reports the research of the Schwille Group at the Max Planck Institute of Biochemistry near Munich using the NanoWizard® ULTRA Speed AFM October 24th, 2017

GTC Shanghai Highlights GF’s Momentum in China: Company shares details of technology roadmap and customer adoption in the world’s fastest-growing market for semiconductors October 23rd, 2017

Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma October 23rd, 2017

Patents/IP/Tech Transfer/Licensing

Picosun’s ALD nanolaminates improve lifetime and reliability of electronic circuit boards October 24th, 2017

Novel 'converter' heralds breakthrough in ultra-fast data processing at nanoscale: Invention bagged four patents and could potentially make microprocessor chips work 1,000 times faster October 20th, 2017

Nanoparticles limit damage in spinal cord injury: Injection after an injury reduces inflammation and scarring September 6th, 2017

More durable, less expensive fuel cells: University of Delaware researchers have developed a new technology that could speed up the commercialization of fuel cell vehicles September 5th, 2017

Acquisitions/Mergers/Splits

Bruker Announces Acquisition of Nanoindenting Leader Hysitron: Acquisition strengthens Bruker’s leading position in nanoanalysis and nanomechanical materials characterization January 24th, 2017

GLOBALFOUNDRIES Completes Acquisition of IBM Microelectronics Business: Transaction adds differentiating technologies, world-class technologists, and intellectual property July 1st, 2015

Entest BioMedical, Inc. in Discussions to Acquire Nanotechnology Delivery System for Cancer Therapy June 3rd, 2015

Evident Thermoelectrics Acquires GMZ Energy: Investment Accelerates Launch Of Evident's Thermoelectric Modules For Waste Heat May 20th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project